{"id":2280,"date":"2024-08-08T13:57:57","date_gmt":"2024-08-08T13:57:57","guid":{"rendered":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/?page_id=2280"},"modified":"2024-08-08T13:57:57","modified_gmt":"2024-08-08T13:57:57","slug":"what-challenges-will-fda-face-in-a-post-chevron-world","status":"publish","type":"page","link":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/","title":{"rendered":"What Challenges Will FDA Face In A Post-Chevron World?"},"content":{"rendered":"<div class=\"article-meta\">\r\n  <p class=\"author\">By Brenda Sandburg<\/p>\r\n  <p class=\"date\">August 06, 2024<\/p>\r\n<\/div>\r\n\r\n<p>The US Supreme Court\u2019s decision eliminating Chevron deference for federal agencies is expected to have enormous repercussions for the Food and Drug Administration as it faces a potential surge in lawsuits challenging its regulations and policies on a range of issues, from drug approvals to drug exclusivity and off-label use.<\/p> \r\n\r\n<p>The Supreme Court\u2019s June 28 decision in <em>Loper Bright Enterprises v. Raimondo<\/em> overruled its 1984 opinion in <em>Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc<\/em>. In Chevron, the high court held that if courts find that a statue administered by a federal agency is ambiguous about an issue, they should defer to the agency\u2019s interpretation of it.<\/p> \r\n\r\n<p>In <em>Loper<\/em>, the court held 6-3 that this deference cannot be squared with the Administrative Procedure Act, which requires courts to exercise their independent judgment in deciding whether an agency has acted within its statutory authority. \u201cChevron cannot be reconciled with the <abbr title=\"Administrative Procedure Act\">APA<\/abbr> by presuming that statutory ambiguities are implicit delegations to agencies,\u201d the opinion, written by Chief Justice John Roberts, Jr., states. \u201cCourts may not defer to an agency interpretation of the law simply because a statute is ambiguous.\u201d<\/p>\r\n\r\n<p>Legal experts say it may take years to see how courts implement the decision. But they expect FDA will be more cautious and take more time in formulating policies to avoid legal challenges.<\/p>\r\n\r\n<p>\u201cI think FDA and all federal agencies are worried that more and more of their decisions are going to be second-guessed, and that they&#8217;re going to find themselves in court a lot more often than they had in the past only because they won&#8217;t be getting the deference that they had traditionally been getting,\u201d Chad Landmon, chair of Polsinelli\u2019s Hatch-Waxman and Biologics Practice, said.<\/p> \r\n\r\n<h5>Drug Approvals and Exclusivities<\/h5>\r\n\r\n<p>Landmon said FDA decisions based on the agency\u2019s interpretation of a statute, such as decisions relating to a drug\u2019s exclusivity \u2014 for dosage form, new chemical entity, orphan drug or 180-day generic drug exclusivity \u2014 are more likely to be challenged. He said FDA and industry are particularly concerned about whether courts will defer to the agency\u2019s scientific determinations.<\/p>\r\n\r\n<a href=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/agenda\/\" target=\"_blank\" style=\"display: block; width: fit-content; margin: 0 auto 36px;\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png\" alt=\"PIV Chicago\" width=\"728\" height=\"90\"><\/a>  \r\n\r\n<p>\u201cI think that judges will look at the safety and effectiveness determinations and defer to the agency on the pure scientific conclusions. But I think judges may be a little more willing to go under the tent and say, \u201cwhat did you consider to get there and were your considerations consistent with what the statute says and the authority that Congress has given you?\u201d Landmon stated. \u201cI think that\u2019s kind of a big open question going forward.\u201d<\/p>\r\n\r\n<p>Eva Temkin, a partner at Arnold &#038; Porter and former FDA associate chief counsel and policy advisor, said the question she has been asked most often about the Loper decision is what it means for drug approvals. \u201cI think we don\u2019t fully know yet,\u201d she said.<\/p> \r\n\r\n<p>She noted that the Supreme Court distinguished between <abbr title=\"Administrative Procedure Act\">APA<\/abbr> review of agency actions on legal questions and review of factual decisions. The majority said the APA specifies that courts, not agencies, will decide \u201call relevant questions of law\u201d arising on review of agency actions but mandates \u201cthat judicial review of agency policymaking and factfinding be deferential.\u201d<\/p>\r\n\r\n<p>Temkin said whether the data in a new drug application or biologics license application demonstrates substantial safety and efficacy can be a legal question, a fact question, or both, and in some cases there might be room for courts to revisit what is enough evidence to be deemed substantial.<\/p>\r\n\r\n<p>Many interpretive issues could come under scrutiny in the wake of <em>Loper<\/em>, Temkin said, including FDA\u2019s drug exclusivity, intended use, and combination product regulations. She noted that the Supreme Court further expanded the regulations that parties may challenge in its July 1 decision in <em>Corner Post, Inc. v. Board of Governors of the Federal Reserve System<\/em>.<\/p> \r\n\r\n<p>In that case, the court held 6-3 that the statute of limitations for bringing a civil action against the United States under the APA does not begin to run until the plaintiff is injured by a final agency action. The Eighth Circuit had held that the statute of limitations period begins upon publication of the regulation. But for <em>Corner Post<\/em>, Temkin said, challenges would focus on relatively recent regulations. \u201cNow new entrants to the market have the opportunity to bring a challenge based on the time of injury as opposed to the time of the rulemaking, which opens the door to challenging things like the intended use regulations,\u201d she said.<\/p>\r\n\r\n<h5>Will Previous Cases Be Reopened?<\/h5>\r\n\r\n<p>The Supreme Court said that by overruling <em>Chevron<\/em>, it did not call into question prior cases that relied on the Chevron framework. The holdings in those cases are still subject to stare decisis, the doctrine that courts will adhere to precedent in making their decisions.<\/p>\r\n\r\n<p>However, as the majority did in overruling <em>Chevron<\/em> based on finding that the decision was misguided and unworkable, lower courts could apply such factors in overruling other decisions.<\/p> \r\n\r\n<a href=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/agenda\/\" target=\"_blank\" style=\"display: block; width: fit-content; margin: 0 auto 36px;\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png\" alt=\"PIV Chicago\" width=\"728\" height=\"90\"><\/a>  \r\n\r\n<p>Landmon said in cases involving mostly a legal review of an interpretation of a statute, a company could bring the same or similar challenge in a different circuit. \u201cI think they\u2019re still potentially ripe for legal challenges without deference in a <em>post-Chevron<\/em> world,\u201d he said.<\/p>\r\n\r\n<p>One such case involving a statuary interpretation is <em>Catalyst Pharmaceuticals, Inc. v. Becerra<\/em>. The US Court of Appeals for the Eleventh Circuit found that FDA misinterpreted the Orphan Drug Act in approving Jacob\u2019s Pharmaceutical Company\u2019s Ruzurgi (amifampridine) for treatment of a rare immune disorder in pediatric patients when Catalyst had orphan exclusivity for its amifampridine product Firdapse for treatment of adults with the same condition.<\/p> \r\n\r\n<p>While many FDA decisions could now be open to second-guessing, Temkin said clarity and predictability remain very important to industry. \u201cI don\u2019t think that industry wants a free-for-all. I think that there will be reasonable challenges brought based on statutory text where previously there may have been concerns about overcoming deference, or maybe there will be a decision in a litigation to seek a preliminary injunction,\u201d she said.<\/p> \r\n\r\n<p>As for the practical effect of the ruling on FDA, Temkin expects the agency will issue less rulemaking because there will be less of an incentive to do so without deference. Landmon said it remains to be seen whether the agency will pursue decion-making through guidance. He noted that some think the agency will do so because guidances are not binding while others think guidances are more questionable in the wake of <em>Loper<\/em>.<\/p>\r\n\r\n<h5>Agency May Be Persuasive on Some Questions<\/h5>\r\n\r\n<p>At issue in <em>Loper<\/em> was whether agencies have more expertise than judges to interpret the statutes they administer.  The majority asserted that <em>Chevron\u2019s<\/em> presumption that Congress implicitly delegated to agencies the authority of interpreting statutory ambiguities \u201cis misguided because agencies have no special competence in resolving statutory ambiguities. Courts do.\u201d<\/p>\r\n\r\n<p>Justice Elena Kagan rebutted this in her dissent, joined by Justices Sonia Sotomayor and Ketanji Brown Jackson.<\/p>\r\n\r\n<p>\u201cIn one fell swoop, the majority today gives itself exclusive power over every open issue \u2014 no matter how expertise-driven or policy-laden \u2014 involving the meaning of regulatory law,\u201d Kagan asserted. \u201cThe idea that courts have \u2018special competence\u2019 in deciding such questions whereas agencies have \u2018no[ne]\u2019 is, if I may say, malarky.\u201d<\/p>\r\n\r\n<p>Kagan said \u201cagencies often know things about a statute\u2019s subject matter that courts could not hope to. The point is especially stark when a statue is of a \u2018scientific or technical nature.\u2019\u201d<\/p> \r\n\r\n<p>For example, she pointed to the case of determining when an alpha amino acid polymer qualifies as a \u201cprotein.\u201d \u201cI don\u2019t know many judges who would feel confident resolving that issue,\u201d Kagan stated. \u201cBut the FDA likely has scores of scientists on staff who can think intelligently about it, maybe collaborate with each other on its finer points, and arrive at a sensible answer.\u201d<\/p>\r\n\r\n<p>In February 2020, FDA issued a final rule on the definition of \u201cbiological product,\u201d which states that the term protein means any alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size.<\/p>\r\n\r\n<p>Temkin said the majority left open that courts might find certain kinds of agency decision-making to be persuasive. &#8220;There might still be room for courts to find agencies persuasive on some kinds of questions,\u201d she said. \u201cI think we just don\u2019t really know where the contours of that are going to end up shaking out.\u201d<\/p>\r\n\r\n<p>ACI will be covering the challenges facing FDA in the wake of the <em>Loper<\/em> decision at the <strong>Paragraph IV Disputes Master Symposium in Chicago Oct. 15-16<\/strong>.<\/p>\r\n\r\n<a href=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/agenda\/\" target=\"_blank\" style=\"display: block; width: fit-content; margin: 0 auto 36px;\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png\" alt=\"PIV Chicago\" width=\"728\" height=\"90\"><\/a>  \r\n\r\n<br>\r\n<p style=\"font-size: 14px; line-height: 20px;\"><strong style=\"font-weight: 500;\">For more information, please contact:<\/strong><br>Joanna Chung<br>Associate Director of Marketing<br><span style=\"white-space: nowrap;\">American Conference Institute |<\/span> <span style=\"white-space: nowrap;\">The Canadian Institute |<\/span> C5<br>E:&nbsp;<a href=\"mailto:j.chung@americanconference.com\">j.chung@americanconference.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"By Brenda Sandburg August 06, 2024 The US Supreme Court\u2019s decision eliminating Chevron deference for federal agencies is expected to have enormous repercussions for the Food and Drug Administration as it faces a potential surge in lawsuits challenging its regulations and policies on a range of issues, from drug approvals to drug exclusivity and off-label&hellip;","protected":false},"author":21603,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2280","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>What Challenges Will FDA Face In A Post-Chevron World? | Paragraph IV Disputes<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What Challenges Will FDA Face In A Post-Chevron World? | Paragraph IV Disputes\" \/>\n<meta property=\"og:description\" content=\"By Brenda Sandburg August 06, 2024 The US Supreme Court\u2019s decision eliminating Chevron deference for federal agencies is expected to have enormous repercussions for the Food and Drug Administration as it faces a potential surge in lawsuits challenging its regulations and policies on a range of issues, from drug approvals to drug exclusivity and off-label&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/\" \/>\n<meta property=\"og:site_name\" content=\"Paragraph IV Disputes\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/\",\"url\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/\",\"name\":\"What Challenges Will FDA Face In A Post-Chevron World? | Paragraph IV Disputes\",\"isPartOf\":{\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png\",\"datePublished\":\"2024-08-08T13:57:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#primaryimage\",\"url\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png\",\"contentUrl\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png\",\"width\":655,\"height\":129},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What Challenges Will FDA Face In A Post-Chevron World?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/#website\",\"url\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/\",\"name\":\"Paragraph IV Disputes\",\"description\":\"Template used to create new conference sites\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"What Challenges Will FDA Face In A Post-Chevron World? | Paragraph IV Disputes","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/","og_locale":"en_US","og_type":"article","og_title":"What Challenges Will FDA Face In A Post-Chevron World? | Paragraph IV Disputes","og_description":"By Brenda Sandburg August 06, 2024 The US Supreme Court\u2019s decision eliminating Chevron deference for federal agencies is expected to have enormous repercussions for the Food and Drug Administration as it faces a potential surge in lawsuits challenging its regulations and policies on a range of issues, from drug approvals to drug exclusivity and off-label&hellip;","og_url":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/","og_site_name":"Paragraph IV Disputes","og_image":[{"url":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/","url":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/","name":"What Challenges Will FDA Face In A Post-Chevron World? | Paragraph IV Disputes","isPartOf":{"@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#primaryimage"},"image":{"@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#primaryimage"},"thumbnailUrl":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png","datePublished":"2024-08-08T13:57:57+00:00","breadcrumb":{"@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#primaryimage","url":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png","contentUrl":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-content\/uploads\/sites\/1994\/2024\/07\/815L25_banners_article_1.png","width":655,"height":129},{"@type":"BreadcrumbList","@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/what-challenges-will-fda-face-in-a-post-chevron-world\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/"},{"@type":"ListItem","position":2,"name":"What Challenges Will FDA Face In A Post-Chevron World?"}]},{"@type":"WebSite","@id":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/#website","url":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/","name":"Paragraph IV Disputes","description":"Template used to create new conference sites","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/pages\/2280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/users\/21603"}],"replies":[{"embeddable":true,"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/comments?post=2280"}],"version-history":[{"count":3,"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/pages\/2280\/revisions"}],"predecessor-version":[{"id":2284,"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/pages\/2280\/revisions\/2284"}],"wp:attachment":[{"href":"https:\/\/www.americanconference.com\/paragraph-iv-disputes-master-symposium\/wp-json\/wp\/v2\/media?parent=2280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}